skin.dermsquared.com Open in urlscan Pro
51.81.109.158  Public Scan

Form analysis
1 forms found in the DOM

POST https://skin.dermsquared.com/skin/search/search

<form class="navbar-form navbar-left" role="search" method="post" action="https://skin.dermsquared.com/skin/search/search">
  <div class="form-group">
    <input class="form-control" name="query" value="" type="text" aria-label="Search Query" placeholder="">
  </div>
  <button type="submit" class="btn btn-default">Search</button>
</form>

Text Content

Quick jump to page content
 * Main Navigation
 * Main Content
 * Sidebar


 * Register
 * Login


Toggle navigation




 * Home
 * About
   * About the Journal
   * Submissions
   * Editorial Team
   * Privacy Statement
   * Contact
 * Current
 * Archives
 * Submission
 * Dermsquared


Search

 



 




ABOUT THE JOURNAL

SKIN is a peer-reviewed, open access, online only journal dedicated to providing
free access globally to disseminate dermatological knowledge. Authors retain
copyright in their articles, licensing publication of their content through use
of Creative Commons CCBY license. The journal does not charge fees, and is
supported by the National Society for Cutaneous Medicine. 


Read More


CURRENT ISSUE

Vol. 8 No. 6 (2024): November 2024 Issue

Published: 2024-11-18

ISSUE HIGHLIGHTS


IN-DEPTH REVIEWS


ALLERGENS CAUSING ALLERGIC CONTACT DERMATITIS IN COSMETIC PRODUCTS: A SYSTEMATIC
REVIEW

Trya Oktaviani, Suci Widhiati, Harijono Kariosentono , Muhammad Eko Irawanto,
Triasari Oktavriana

Page 1908-1919

PDF KOL SUMMARY


A SYSTEMATIC REVIEW OF THE ASSOCIATION OF ELASTOSIS PERFORANS SERPIGINOSA AND
CONGENITAL DISORDERS

Carolyn Heckman, Elizabeth Flatley, Rucha Janodia

Page 1920-1933

PDF


TISSUE-ENGINEERED SKIN SUBSTITUTES FOR USE IN CLINICAL DERMATOLOGICAL PRACTICE

Kaitlyn Ramsay, Katarina Laketic, Maria Hangad, Samiha Mohsen

Page 1934-1945

PDF KOL SUMMARY


ORIGINAL RESEARCH


HOW AUTOMATION IN ELECTRONIC MEDICAL RECORDS CAN LEAD TO ERRORS IN DERMATOLOGY

Kaycee Nguyen, Clay J. Cockerell MD, MBA, JD

Page 1946-1951

PDF


EFFECTS OF MINERAL AND ALMOND OIL ADMINISTRATION ON TRANSEPIDERMAL WATER LOSS
AND SKIN ACIDITY IN CHRONIC RENAL FAILURE PATIENTS UNDERGOING HEMODIALYSIS

Trya Oktaviani, Endra Yustin Ellistasari, Benedikta Lauda Anandita

Page 1952-1958

PDF


MEDICAL EDUCATION IN DERMATOLOGY


IMPOSTER SYNDROME IN DERMATOLOGY

Michael Brennan, Audrey Fotouhi, Steven Daveluy

Page 1959-1965

PDF


PUBLICATION OUTCOMES OF ABSTRACTS PRESENTED AT THE 2020 SOCIETY FOR
INVESTIGATIVE DERMATOLOGY ANNUAL MEETING

Madeline Brown, Priscilla Mammen, Dakarai Dunbar, Albert Zhou, Hao Feng

Page 1966-1970

PDF


RESEARCH LETTERS


INVESTIGATING THE IMPACT OF FINANCIAL SPONSORSHIP IN DERMATOLOGY RESEARCH

Umayr Shaikh, Ayushya Ajmani, David Makaj, Payal Shah

Page 1971-1973

PDF


BRIEF ARTICLES


A CASE OF CUTANEOUS SQUAMOUS CELL CARCINOMA TREATED WITH NEOADJUVANT CEMIPLIMAB

Iraj Hasan, Mary Garland-Kledzik

Page 1974-1977

PDF


EOSINOPHIL-RICH LINEAR IGA BULLOUS DERMATOSIS: A CASE REPORT OF A RARE ENTITY

Celter Odango, MS, Grace Im, MS, Abigail C. Wills, MD, Sarah Gradecki, MD,
Richard H Flowers, MD

Page 1978-1980

PDF


PALMOPLANTAR PSORIASIS TREATMENT WITH TOPICAL ROFLUMILAST 0.3%

Diego Ruiz Dasilva

Page 1981-1983

PDF


SUCCESSFUL TREATMENT OF PERIORAL DERMATITIS WITH UPADACITINIB

Anya Patel, William Lau, Mark Lebwohl

Page 1984-1986

PDF


PITYRIASIS RUBRA PILARIS, REFRACTORY TO IL-17A INHIBITION, WITH RAPID
IMPROVEMENT FOLLOWING IL-17A/IL-17F BLOCKADE BY BIMEKIZUMAB

Jeremy Orloff, Grayson Domzalski, Shivkar Amara, Mark Lebwohl

Page 1987-1992

PDF


MULTIPLE INJECTION SITE REACTIONS AFTER TREATMENT WITH DIFFERENT BIOLOGICS FOR
PSORIASIS AND PSORIATIC ARTHRITIS

Grayson Domzalski, William C. Lau, BA, Rebecca Barzi, RN, Rachel L. Miller, MD,
Mark G. Lebwohl, MD

Page 1993-1996

PDF


THE TREATMENT OF LICHEN SCLEROSUS WITH TOPICAL ROFLUMILAST 0.3% CASE STUDY

Erik Domingues

Page 1997-2000

PDF


SCLEROTIC FIBROMA IN A PATIENT WITH BIRT-HOGG-DUBÉ SYNDROME

Pelin Sagut, Nicholas Strat, Elston Dirk

Page 2001-2005

PDF


CONCOMITANT ERUPTIVE SQUAMOUS ATYPIA AND BULLOUS DRUG ERUPTION ASSOCIATED WITH
PEMBROLIZUMAB

Kevin Yang, MD, Hoang Ho-Pham, MD, Jordan Beam, BS, Lauren Kole, MD

Page 2006-2010

PDF


THE NON-HEALING WOUND: AN EARLY CLUE TO CALCIPHYLAXIS

Carlie Reeves

Page 2011-2015

PDF


A CASE OF ZOONOTIC DOMESTICALLY ACQUIRED HANSEN DISEASE (LEPROSY) IN THE STATE
OF GEORGIA

Daniel Nicolle, Jodi Ganz, Melinda Mohr

Page 2016-2020

PDF


UTILIZING UPADACITINIB FOR THE MANAGEMENT OF HAILEY-HAILEY DISEASE

Hayden Y. K. Fung, William Lau, Mark Lebwohl

Page 2021-2024

PDF


CARPAL TUNNEL CORTICOSTEROID INJECTION TREATMENT OF NAIL LICHEN PLANUS

Miranda Lee-Foltz, Payal Shah, Denise Aaron

Page 2025-2028

PDF


PHOTOSENSITIVITY DERMATITIS ASSOCIATED WITH THE MODERNA BOOSTER VACCINATION

Hadley Hudson, Milaan Shah

Page 2029-2033

PDF


SKINMAGES: CLINICAL IMAGES IN DERMATOLOGY


CUTANEOUS MANIFESTATIONS OF THE HEMISCORPIUS LEPTURUS STINGS

Hossein Sanaei-Zadeh

Page 2034-2036

PDF


THE PENILE LYMPHATIC MALFORMATION CAUSING URINARY OBSTRUCTION

Khalid Al Aboud, Ahmad Al Aboud, Daifullah Al Aboud

Page 2037-2039

PDF


PEDIATRIC VISCEROCUTANEOUS LOXOSCELISM: A WEB OF CLINICAL CHALLENGES

Meagan Olivet, James Clayton Parker, Tiffany Mayo

Page 2040-2041

PDF


POSTER PRESENTATIONS FROM FC24 DERMATOLOGY CONFERENCE®: PSORIASIS


RECALCITRANT SCALP PSORIASIS SUCCESSFULLY TREATED WITH ONCE-DAILY ROFLUMILAST
CREAM 0.3%

ERIK DOMINGUES

Page s417

PDF


IXEKIZUMAB IMPROVES NAIL, SCALP, AND SKIN RESPONSE AND QUALITY OF LIFE
INDEPENDENT OF BASELINE PSORIASIS SEVERITY: RESULTS FROM THE PSORIASIS IN
SPECIAL AREAS (PSOSA) STUDY

Shari Lipner, Cindy Owen, Neil Korman, William Malatestinic, Meghan Feely
McDonald, Mwangi James Murage, Ali Sheikhi Mehrabadi, Joseph Merola

Page s418

PDF


DEUCRAVACITINIB IN PLAQUE PSORIASIS: LABORATORY PARAMETERS THROUGH 4 YEARS OF
TREATMENT IN THE PHASE 3 POETYK PSO-1, PSO-2, AND LTE TRIALS

Neil J. Korman, Thierry Passeron, Yukari Okubo, Jerry Bagel, Richard B. Warren,
Lynda Spelman, Kevin Winthrop, Kim Hoyt, Thomas Scharnitz, Subhashis Banerjee,
Diamant Thaçi, Mona Shahriari, Linda Stein Gold

Page s419

PDF


DEUCRAVACITINIB, AN ORAL SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN
PATIENTS WITH MODERATE TO SEVERE SCALP PSORIASIS: EFFICACY AND SAFETY RESULTS OF
A PHASE 3B/4, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL
(PSORIATYK SCALP)

Kristina Callis Duffin, Christopher E. M. Griffiths, Matthias Hoffmann, Andrew
Blauvelt, Eugene Balagula, Andrew Napoli, Ying-Ming Jou, Rachel Dyme, Virginia
Hala, Andreas Pinter, Mark Lebwohl

Page s420

PDF


REAL-WORLD ACHIEVEMENT OF SKIN CLEARANCE TARGETS AND IMPROVED QUALITY OF LIFE
WITH RISANKIZUMAB IN PSORIASIS PATIENTS WITH MODERATE SKIN INVOLVEMENT (BSA ≥
3–10%)

Bruce Strober, Manish Patel, Mark I Kaldas, Greg St John, Vishvas Garg, Adam P
Sima, Thomas Eckmann, Alicia Beeghly, April Armstrong

Page s421

PDF


DEUCRAVACITINIB LONG-TERM EFFICACY THROUGH 4 YEARS IN WEEK 16 PLACEBO CROSSOVER
PATIENTS IN THE PHASE 3 POETYK PSO-1, PSO-2, AND LTE PROGRAM

Mark Lebwohl, Richard B. Warren, Shinichi Imafuku, Jerry Bagel, April W.
Armstrong, Thierry Passeron, Subhashis Banerjee, Matthew J. Colombo, Thomas
Scharnitz, Kim Hoyt, Diamant Thaçi, Andrew Blauvelt

Page s422

PDF


DEUCRAVACITINIB IN PLAQUE PSORIASIS: 4-YEAR SAFETY AND EFFICACY RESULTS FROM THE
PHASE 3 POETYK PSO-1, PSO-2, AND LTE TRIALS

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi
Morita, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim
A. Papp, Matthew J. Colombo, John Vaile, Eleni Vritzali, Kim Hoyt, Carolin
Daamen, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s423

PDF


REAL-WORLD PATIENT USE AND PERCEPTION, SATISFACTION, AND ADHERENCE WITH A
CALCIPOTRIOL AND BETAMETHASONE DIPROPIONATE PAD-CREAM FOR THE TREATMENT OF
PLAQUE PSORIASIS

José Luis López Estebaranz, Hjalmar Kurzen, Marta Menendez, Giulia Greta Dradi,
Jordi Galvan

Page s424

PDF


DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2)
INHIBITOR, IN PATIENTS WITH MODERATE TO SEVERE SCALP PSORIASIS: IMPROVEMENT IN
SCALP-RELATED QUALITY OF LIFE AND SYMPTOMS IN THE PHASE 3B/4 MULTICENTER,
RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PSORIATYK SCALP TRIAL

Steven R. Feldman, Jerry Bagel, Matthias Hoffmann, Andrew Napoli, Chun-Yen
Cheng, Rachel Dyme, Eugene Balagula, Yichen Zhong, Steven E. Kempers,
Christopher E. M. Griffiths

Page s425

PDF


TREATMENTS USED AMONG PATIENTS WITH PSORIASIS: A FIRST LOOK AT A NEW
PATIENT-CENTERED PSORIASIS REGISTRY

Alexis Ogdie, Joel Gelfand, Laetitia N’Dri, Ying Wu, Thomas Scharnitz, Kaleb
Michaud

Page 10.25251/skin.8.supp.426

PDF


PROVIDER BURDEN ASSOCIATED WITH APREMILAST ADVERSE EVENTS

Lana Schmidt, Ying Wu, Vardhaman Patel, Danielle Gentile, Djibril Liassou, Jason
Sharpe, Courtney Omary, Monica Ahlquist, Bruce Feinberg

Page s427

PDF


DEUCRAVACITINIB IN MODERATE TO SEVERE PLAQUE PSORIASIS: COMORBIDITIES AND USE OF
PRIOR AND CONCOMITANT MEDICATION IN PATIENTS ENROLLED IN THE PHASE 3 POETYK
PSO-1 AND PSO-2 TRIALS

Joseph F. Merola, Alice B. Gottlieb, Nehal N. Mehta, Matthew J. Colombo, Monica
Elias, Francesco De Leonardis, Ying-Ming Jou, Neil J. Korman

Page s428

PDF


EFFICACY OF DEUCRAVACITINIB IN PLAQUE PSORIASIS ACROSS A RANGE OF BODY SURFACE
AREA INVOLVEMENT: POST HOC ANALYSIS OF THE RANDOMIZED, DOUBLE-BLINDED,
PLACEBO-CONTROLLED, PHASE 3B/4 PSORIATYK SCALP TRIAL

Andrew Blauvelt, Diamant Thaçi, David M. Pariser, Andrew Napoli, Eugene
Balagula, Chun-Yen Cheng, Rachel Dyme, Linda Stein Gold, Mark Lebwohl

Page s429

PDF


EFFICACY OF DEUCRAVACITINIB IN MODERATE TO SEVERE SCALP PSORIASIS: ANALYSIS OF
COMPLETE CLEARANCE OF SCALP DISEASE AND SYMPTOMS

Linda Stein Gold, Andrew Blauvelt, Leon Kircik, Andrew Napoli, Chun-Yen Cheng,
Rachel Dyme, Eugene Balagula, Jerry Bagel, Mark Lebwohl

Page s430

PDF


BIMEKIZUMAB EFFICACY AND SAFETY OVER 48 WEEKS IN US AND CANADIAN PATIENTS WITH
PSORIASIS WHO HAD A TREATMENT INTERRUPTION AFTER 3 YEARS OF TREATMENT: RESULTS
FROM BE RADIANT

Mark Lebwohl, Kim Papp, Benjamin Ehst, Mark Lomaga, Phoebe Rich, Bruce Strober,
April Armstrong, José M. López Pinto, Markus Kaspar, Delphine Deherder, Maggie
Wang, Ronald Vender

Page s431

PDF


BIMEKIZUMAB 4-YEAR EFFICACY IN HIGH-IMPACT AREAS IN MODERATE TO SEVERE PLAQUE
PSORIASIS: POOLED RESULTS FROM BE BRIGHT

Joseph F. Merola, Alice B. Gottlieb, Jennifer Soung, Philip Hampton, Andreas
Pinter, Melinda Gooderham, Akimichi Morita, Sarah Kavanagh, Nancy Cross, Susanne
Wiegratz, Carle Paul

Page s432

PDF


BIMEKIZUMAB LONG-TERM EFFICACY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE
PSORIASIS AFTER SWITCHING FROM ADALIMUMAB, USTEKINUMAB, OR SECUKINUMAB: RESULTS
FROM UP TO 4 YEARS OF TOTAL TREATMENT FROM BE BRIGHT AND BE RADIANT

Georgios Kokolakis, George Han, David Pariser, Antonio Costanzo, Richard G.
Langley, Rhys Warham, Balint Szilagyi, Bertram Knapp, Mark Lebwohl

Page s433

PDF


BIMEKIZUMAB CLINICAL EFFICACY IN IMPORTANT BODY REGIONS AND HEALTH-RELATED
QUALITY OF LIFE IN PATIENTS WITH PLAQUE PSORIASIS: DATA FROM FOUR PHASE 3/3B
COMPARATOR-CONTROLLED TRIAL PERIODS

April Armstrong, Boni Elewski, Phoebe Rich, Matthias Augustin, José-Manuel
Carrascosa, Ronald Vender, Jérémy Lambert, José M. López Pinto, Bengt Hoepken,
Sarah Kavanagh, Luis Puig

Page s434

PDF


BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS WHO HAD
SKIN AND NAIL PSORIASIS AT BASELINE: UP TO 2-YEAR RESULTS FROM TWO PHASE 3
STUDIES

Diamant Thaçi, Akihiko Asahina, Wolf Henning Boehncke, Alice B. Gottlieb, Mark
Lebwohl, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph
F. Merola

Page s435

PDF


BIMEKIZUMAB SAFE AND EFFECTIVE SELF-ADMINISTRATION USING 2 ML DEVICES BY
PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM TWO MULTICENTER,
RANDOMIZED, OPEN-LABEL STUDIES

Jerry Bagel, Daljit Tatla, Bertram Knapp, Thomas Vaux, Bengt Hoepken, Michael
Sebastian

Page s436

PDF


BIMEKIZUMAB 4-YEAR MAINTENANCE OF RESPONSES IN WEEK 16 RESPONDERS WITH MODERATE
TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE BE BRIGHT OPEN-LABEL EXTENSION
PHASE 3 TRIAL

Andrew Blauvelt, Peter Foley, Richard G. Langley, Curdin Conrad, David Rosmarin,
Ricardo Romiti, Maggie Wang, Balint Szilagyi, Bengt Hoepken, Richard B. Warren

Page s437

PDF


BRODALUMAB VERSUS USTEKINUMAB IN OBESE PATIENTS WITH MODERATE-TO-SEVERE PLAQUE
PSORIASIS

Sylvia Hsu, April Armstrong, Lawrence Green, Mark Lebwohl, Abby Jacobson

Page s438

PDF


FIXED-COMBINATION HALOBETASOL PROPIONATE 0.01% AND TAZAROTENE 0.045% LOTION AND
HALOBETASOL PROPIONATE 0.01% LOTION FOR PLAQUE PSORIASIS ON AREAS WITH BODY
HAIR: MAINTENANCE OF TREATMENT EFFECT

George Han, Edward Lain, Linda Stein Gold, Abby Jacobson

Page s439

PDF


DEMONSTRATION OF THE CLINICAL UTILITY OF A PSORIASIS PRECISION MEDICINE TOOL:
FINDINGS FROM THE MATCH STUDY SHOW ALTERED PHYSICIAN BEHAVIOR LEADS TO IMPROVED
PATIENT OUTCOMES

Tobin Dickerson, Bruce Strober, Michael Bukhalo, April Armstrong, David Pariser,
Leon Kircik, Paul Montgomery, III

Page s440

PDF


ZASOCITINIB (TAK-279), A SELECTIVE, ORAL TYK2 INHIBITOR, REDUCES BODY SURFACE
AREA INVOLVEMENT IN A PHASE 2B TRIAL IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

Vivian Laquer, Leon H. Kircik, Neil Sadick, Jamie Weisman, Jessamyn Blau, Wenwen
Zhang, Jonathan Uy, Warren Winkelman, Melinda Gooderham

Page s441

PDF


EVALUATION OF CHANGES IN LABORATORY PARAMETERS FROM A PHASE 2B TRIAL OF
ZASOCITINIB (TAK-279), AN ORAL, SELECTIVE TYK2 INHIBITOR, IN PATIENTS WITH
MODERATE-TO-SEVERE PLAQUE PSORIASIS

Melinda Gooderham, Christopher Bunick, Leon H. Kircik, Charles Lynde, Lone Skov,
Jessamyn Blau, Wenwen Zhang, Jonathan Uy, Warren Winkelman, Diamant Thaçi

Page s442

PDF


REAL-WORLD SWITCH RATES OF RISANKIZUMAB AND OTHER BIOLOGICS IN PSORIASIS
PATIENTS WITH PSORIATIC ARTHRITIS

April W. Armstrong, Manish Patel, Zachary R. Babcock, Chao Li, Jashin J. Wu

Page s443

PDF


PSORIATIC ARTHRITIS


MAINTENANCE OF RESPONSE TO RISANKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: A
4-YEAR ANALYSIS OF THE KEEPSAKE 1 AND 2 TRIALS

Andrew Östör, Lila Glotfelty, Jonathon Rocco, Cuiyong Yue, Joseph F Merola

Page s444

PDF


LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB FOR CSDMARD-IR PATIENTS WITH
ACTIVE PSORIATIC ARTHRITIS: 196-WEEK RESULTS FROM THE KEEPSAKE 1 TRIAL

Frank Behrens, Mauro Keiserman, Kim Papp, Douglas White, Angela Crowley,
Tshepiso Madihlaba, Thomas Iyile, Kyle Carter, Ahmed Soliman, Doug Ashley, Lily
Glotfelty

Page s445

PDF


LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS:
196-WEEK RESULTS FROM THE KEEPSAKE 2 TRIAL

Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco,
Jacob Aelion, Ana Biljan, Jonathon Rocco, Fang Liu, Ahmed Soliman, Doug Ashley,
Lila Glotfelty, Alan Kivitz

Page s446

PDF


RETROSPECTIVE ANALYSIS OF THE IMPACT OF SCREENING FOR PSORIATIC ARTHRITIS (PSA)
WITH THE PSORIASIS EPIDEMIOLOGY SCREENING TOOL (PEST) IN CLINICAL DERMATOLOGY
PRACTICE

Lawrence Rasouliyan, Uche Ndefo, Amanda Mummert, Amanda Althoff, Robert Low

Page s447

PDF


ATOPIC DERMATITIS


UTILIZATION AND DURATION OF SYSTEMIC CORTICOSTEROID EXPOSURE IN ATOPIC
DERMATITIS PATIENTS AFTER THE INTRODUCTION OF ADVANCED THERAPIES: A
POPULATION-BASED STUDY FROM THE UNITED STATES

Christopher Bunick, Ruth Ann Vleugels, Mark Lebwohl, Ayman Grada, Emma Xiaomeng
Yue, Lani Wegrzyn, Elvira D'Andrea

Page s448

PDF


LONG-TERM MAINTENANCE OF OPTIMAL TREATMENT TARGETS FOR SKIN AND ITCH OUTCOMES
WITH UPADACITINIB IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: 140-WEEK RESULTS FROM
THE PHASE 3 MEASURE UP 1 AND 2 STUDIES

Naiem T Issa, Raj Chovatiya, Jordan Talia, Tiago Torres, Kilian Eyerich, Brian M
Calimlim, Yang Yang, Alena Pechonkina, Alvaro Moreira, Ayman Grada, Christopher
G Bunick

Page s449

PDF


REAL-WORLD EFFECTIVENESS OF UPADACITINIB IN MODERATE‑TO‑SEVERE ATOPIC DERMATITIS
(AD): RESULTS FROM LONGITUDINAL ANALYSES OF THE COREVITAS AD REGISTRY

Jonathan I. Silverberg, Melinda Gooderham, Christopher G. Bunick, Brian
Calimlim, Ayman Grada, Yolanda Muñoz Maldonado, Alvin Li, Nicole Fergestrom,
Eric Simpson

Page s450

PDF


SWITCHING FROM DUPILUMAB TO UPADACITINIB IN ADULTS AND ADOLESCENTS WITH
MODERATE-TO-SEVERE ATOPIC DERMATITIS AND INADEQUATE RESPONSE TO DUPILUMAB:
EFFICACY AND SAFETY RESULTS FROM THE PHASE 3B/4 LEVEL UP STUDY

Christopher Bunick, Nina Magnolo, Angela Moore, Gao Xinghua, Charles Lynde,
Nadia Ibrahim, Ayman Grada, Gweneth Levy, Brian Calimlim, Xiaoqiang Wu, Yolanda
Armendariz, Kilian Eyerich

Page s451

PDF


OPTIMIZED SECOND-GENERATION IL-4RΑ INHIBITION: STRUCTURAL AND MOLECULAR DYNAMICS
PROPERTIES OF RADEMIKIBART FAB-IL-4RΑ COMPLEX

Yuanjun Shi, Minh Ho, Haote Li, Raul Collazo, Christopher Bunick

Page s452

PDF


EFFICACY AND SAFETY OF RUXOLITINIB CREAM BY ANATOMIC REGION IN CHILDREN AGED 2
TO 11 YEARS WITH ATOPIC DERMATITIS: RESULTS FROM TRUE-AD3

Dareen Siri, Amy Paller, April Armstrong, Linda Stein Gold, Howard Kallender,
Daniel Sturm, Haobo Ren, Lawrence Eichenfield

Page s453

PDF


DRYING OF OPZELURA® (RUXOLITINIB) CREAM 1.5%: IMPLICATIONS FOR CLINICAL AND
REAL-WORLD USE

Haydar Abdalghafor, Janel Torsiello, Daniel Sturm, Adnan Nasir, Russell Elliott,
Ahmad Naim

Page s454

PDF


ASSOCIATION OF RUXOLITINIB CREAM INITIATION WITH CONTINUED REDUCTION IN USE OF
OTHER TOPICAL TREATMENTS, ORAL CORTICOSTEROIDS, AND BIOLOGICS FOR ATOPIC
DERMATITIS

Jinan Liu, Karishma Desai, Chia-Chen Teng, Grace Stockbower, Peter Chen, Vincent
Willey, Daniel Sturm

Page s455

PDF


HALF-LIFE-EXTENDED MONOCLONAL ANTIBODY APG777 FOR ATOPIC DERMATITIS: DESIGN OF
THE PHASE 2 APEX STUDY

Emma Guttman-Yassky, Andrew Blauvelt, Melinda Gooderham, Kenji Kabashima,
Marilia Oliveira, Li Xie, Angela Wilson, Carl Dambkowski, Kristine Nograles,
Jonathan Silverberg

Page s456

PDF


DUPILUMAB DEMONSTRATES A HIGHER LIKELIHOOD OF ACHIEVING IMPROVEMENTS IN SIGNS,
SYMPTOMS, AND QUALITY OF LIFE VS. TRALOKINUMAB AT WEEK 16: RESULTS FROM A BUCHER
INDIRECT TREATMENT COMPARISON

Yann Cabon, Boya Chandrasekhar, Chien-chia Chuang, Zhixiao Wang, Ana Rossi,
Kerry Noonan, Mike Bastian

Page s457

PDF


PATIENT AND PARENT/CAREGIVER SATISFACTION WITH EFFICACY AND COSMETIC ELEGANCE OF
TAPINAROF CREAM 1% ONCE DAILY IN A LONG-TERM EXTENSION TRIAL IN ADULTS AND
CHILDREN DOWN TO AGE 2 YEARS WITH ATOPIC DERMATITIS

Adelaide A. Hebert, James Del Rosso, Sandra Marchese Johnson, Lawrence J. Green,
Sarah Serrao, Philip M. Brown, David S. Rubenstein, Anna Tallman

Page s458

PDF


ACHIEVEMENT OF NO-TO-MINIMAL ITCH AND SLEEP IMPROVEMENT WITH TAPINAROF CREAM 1%
ONCE DAILY IN TWO PIVOTAL PHASE 3 TRIALS IN ADULTS AND CHILDREN DOWN TO 2 YEARS
OF AGE WITH ATOPIC DERMATITIS

Eric Simpson, Dareen D. Siri, Raj Chovatiya, Mona Shahriari, Autumn F. Burnette,
Brittany G. Craiglow, Philip M. Brown, Anna Tallman

Page s459

PDF


SKIN CLEARANCE, TREATMENT RESPONSE OFF-THERAPY, AND SAFETY OF TAPINAROF CREAM 1%
ONCE DAILY: RESULTS FROM ADORING 3, A 48-WEEK PHASE 3 TRIAL IN ADULTS AND
CHILDREN DOWN TO 2 YEARS OF AGE WITH ATOPIC DERMATITIS

Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric Simpson, Lawrence F.
Eichenfield, John Browning, Adelaide A. Hebert, Andrew F. Alexis, Weily Soong,
Stephen C. Piscitelli, Anna Tallman, David S. Rubenstein, Philip M. Brown,
Jonathan I. Silverberg

Page s460

PDF


WHY DO OPTIMAL TARGETS FOR ITCH AND SKIN CLEARANCE MATTER IN ATOPIC DERMATITIS
TREATMENT? INSIGHTS FROM TARGET-DERM AD REGISTRY

Jonathan I. Silverberg, Christopher G. Bunick, Brian M. Calimlim, Ayman Grada,
Keith D. Knapp, Breda Munoz, Julie M. Crawford, Chibuzo Obi, Amy S. Paller

Page s461

PDF


PERSISTENT INADEQUATE DISEASE CONTROL AND THERAPEUTIC INERTIA IN
MODERATE-TO-SEVERE ATOPIC DERMATITIS: A 12-MONTH LONGITUDINAL ANALYSIS OF
REAL-WORLD OUTCOMES FROM THE TARGET-DERM AD REGISTRY

Lawrence F. Eichenfield, Ayman Grada, Keith Knapp, Breda Munoz, Julie M.
Crawford, Jonthan I. Silverberg

Page s462

PDF


IMPACT OF THERAPEUTIC INERTIA ON PATIENT-REPORTED OUTCOMES IN MODERATE-TO-SEVERE
ATOPIC DERMATITIS: A 12-MONTH LONGITUDINAL STUDY FROM THE TARGET-DERM AD
REGISTRY

Brenda Simpson, Ayman Grada, Keith Knapp, Breda Munoz, Julie M. Crawford,
Jonathan I. Silverberg

Page s463

PDF


ALOPECIA


DIFFERENTIATING BETWEEN CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA, TRACTION
ALOPECIA, AND ALOPECIA AREATA IN BLACK PATIENTS: PHOTOGRAPHIC EXAMPLES FROM A
CLINICAL TRIAL

Amy McMicheal, Susan Taylor, Valerie Callender, Tiffany Mayo, Susan Ball, Fionn
McSwiney, Najwa Somani, Chesanna Kindred

Page s464

PDF


DISTRIBUTION OF SALT SCORES WITH RITLECITINIB TREATMENT UP TO 24 MONTHS FROM THE
ALLEGRO PHASE 2B/3 AND LONG-TERM PHASE 3 CLINICAL STUDIES IN ALOPECIA AREATA

Ziad Reguiai, Leila Asfour, Delphine Staumont-Sallé, Ángela Hermosa-Gelbard,
Andrea Sechi, Dalia Wajsbrot, Rahmat Adejumo, Deborah Woodworth, Alexandre
Lejeune

Page s465

PDF


CHARACTERIZING LIPID CHANGES AND USE OF LIPID-LOWERING MEDICATIONS IN PATIENTS
WITH ALOPECIA AREATA TREATED WITH BARICITINIB: INTEGRATED RESULTS FROM THE
BRAVE-AA1 AND -AA2 CLINICAL TRIALS

Ruth Ann Vleugals, Arash Mostaghimi, Rodney Sinclair, Bianca Maria Piraccini,
Angelina Sontag, Najwa Somani, Karen Denning, Ayush Srivastava, Brett King

Page s466

PDF


PATIENT PROFILE AND TREATMENT CHARACTERISTICS OF EARLY RITLECITINIB INITIATORS
IN THE US

Samantha K. Kurosky, Liza Takiya, Kent Hanson, Griffith Bell, Yi-Chien Lee,
Genevieve Gauthier

Page s467

PDF


EFFICACY OF RITLECITINIB IN PATIENTS WITH ALOPECIA AREATA BY EXTENT OF HAIR
LOSS: RESULTS FROM THE PHASE 2B/3 AND PHASE 3 ALLEGRO CLINICAL TRIALS

Arash Mostaghimi, Cheshana Kindred, Pedro Herranz Pinto, Masato Mizuashi, Dalia
Wajsbrot, Rahmat Adejumo, Helen Tran, Liza Takiya

Page s468

PDF


RACE AND ETHNICITY SUB-GROUPS OF ALOPECIA AREATA PATIENTS HAVE DIFFERING
CLINICAL CHARACTERISTICS: TARGET-DERM AA

Maria K Hordinsky, Claire C Bristow, Sven G. Richter, Ahmed M. Soliman, Keith
Knapp, Breda Munoz, Julie M. Crawford, Amy S. Paller, Shane Chapman, Lara Wine
Lee, Natasha A. Mesinkovska, Benjamin N. Unger

Page s469

PDF


DEMOGRAPHICS AND DISEASE CHARACTERISTICS OF PATIENTS WITH ALOPECIA AREATA WITH
COMORBID ATOPIC DERMATITIS, VITILIGO OR ANXIETY/DEPRESSION: TARGET-DERM AA

Natasha A Mesinkovska, Sven G. Richter, Claire C Bristow, Ahmed M Soliman, Julie
M Crawford, Keith D Knapp, Breda Munoz, Lara Wine Lee, M. Shane Chapman, Amy S
Paller, Benjamin N Ungar, Maria K Hordinsky

Page s470

PDF


GENERIC VS. DISEASE-SPECIFIC PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS FOR
ASSESSING HRQOL BURDEN AMONG PATIENTS DIAGNOSED WITH ALOPECIA AREATA: EVIDENCE
FROM TARGET-DERM AA

Benjamin N Ungar, Ahmed M. Soliman, Claire C. Bristow, Sven G. Richter, Breda
Munoz, Julie M. Crawford, Keith D. Knapp, Natasha A. Mesinkovska

Page s471

PDF


A NOVEL NUTRACEUTICAL GUMMY FOR HAIR REGROWTH IN WOMEN: A CASE SERIES

Annyella Douglas, Leena Ramani, Spencer Hawkins, Matt Leavitt

Page s472

PDF


HIDRADENITIS SUPPURATIVA


BIMEKIZUMAB EFFICACY AND SAFETY THROUGH 2 YEARS IN PATIENTS WITH HIDRADENITIS
SUPPURATIVA: RESULTS FROM THE PHASE 3 BE HEARD I&II TRIALS AND OPEN-LABEL
EXTENSION BE HEARD EXT

Christos C Zouboulis, Amit Garg, Christopher J. Sayed, Gregor Jemec, Georgios
Kokolakis, John R. Ingram, Akimichi Morita, Pratiksha Dokhe, Ingrid Pansar,
Robert Rolleri, Christina Crater, Asim Datye, Alexa B. Kimball

Page s473

PDF


BIMEKIZUMAB EFFECT ON THE NEED FOR CONCOMITANT RESCUE INTERVENTIONS BY HISCR
RESPONSE LEVEL IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA FROM
BE HEARD I&II

Falk G. Bechara, Seth Forman, Amit Garg, Philippe Guillem, Hesel H. van der Zee,
Evangelos J. Giamarellos-Bourboulis, Akimichi Morita, Bartosz Lukowski, Robert
Rolleri, Pratiksha Dokhe, Nicola Tilt, Iltefat Hamzavi

Page s474

PDF


BIMEKIZUMAB IMPACT ON DRAINING TUNNELS: A DYNAMIC ASSESSMENT IN PATIENTS WITH
MODERATE TO SEVERE HS USING POOLED WEEK 48 RESULTS FROM BE HEARD I&II

Thrasyvoulos Tzellos, Jennifer Hsiao, Martina Porter, Farida Benhadou, Falk G.
Bechara, Melinda Gooderham, Hidetoshi Takahashi, Christos C Zouboulis, Ingrid
Pansar, Robert Rolleri, Nicola Tilt, Christopher Sayed

Page s475

PDF


BIMEKIZUMAB IMPACT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE TO
SEVERE HIDRADENITIS SUPPURATIVA: POOLED WEEK 48 RESULTS FROM BE HEARD I&II

Jacek C Szepietowski, Hadar Lev-Tov, Vivian Y. Shi, Sylke Schneider-Burrus,
Antonio Costanzo, Koremasa Hayama, Jérémy Lambert, Tom Vaux, Bartosz Lukowski,
Robert Rolleri, Alice B Gottlieb

Page s476

PDF


BIMEKIZUMAB CUMULATIVE CLINICAL BENEFIT IN PATIENTS WITH MODERATE TO SEVERE
HIDRADENITIS SUPPURATIVA THROUGH 1 YEAR OF THE BE HEARD I&II PHASE 3 TRIALS

Amit Garg, April Armstrong, Howard Sofen, Antonio Martorell-Calatayud, Maurizio
Podda, Toshifumi Nomura, Susanne Wiegratz, Jérémy Lambert, Robert Rolleri,
Nicola Tilt, Christos C Zouboulis

Page s477

PDF


BARRIERS AND FACILITATORS TO QUALITY HS BIOLOGIC CARE AND OUTCOMES FOR THE
MEDICAID POPULATION ACROSS US STATES

Steven Daveluy, Brindley Brooks, Brent Hazelett, Iltefat Hamzavi, Ginette A.
Okoye, Laura Bush, Jasmine I. Espy, Danuta Marchi, Matthew Rudberg, Tae Oh,
Stephanie Goldberg

Page s478

PDF


MICROWAVE ENERGY FOR MANAGING HIDRADENITIS SUPPURATIVA

Nicole Bielecki DMSc, MSPAS, PA-C, Aaron Hoover, MD

Page s479

PDF


SKIN CANCER


RESULTS OF A PHASE 2 MULTICENTER STUDY EVALUATING THE SAFETY AND TOLERABILITY OF
VP-315, AN INVESTIGATIONAL THERAPY FOR BASAL CELL CARCINOMA

Neal Bhatia MD, Jonathan Kantor MD, Lawrence Green MD, Jonathan Weiss MD,
Cynthia Willson RN, BSN, Susan Cutler DMD, Jayson Rieger PhD, MBA, David K.
Glover ME, PhD, Pamela Rumney RN, CCRC, Thomas F. Haws, Gary Goldenberg MD

Page s480

PDF


RESULTS OF A PHASE 2 MULTICENTER STUDY TO EVALUATE THE EFFICACY OF VP-315, AN
INVESTIGATIONAL THERAPY FOR BASAL CELL CARCINOMA

Jonathan Kantor MD, Neal Bhatia MD, Lawrence Green MD, Jonathan Weiss MD,
Kenneth Y. Tsai, MD, PhD, Cynthia Willson RN, BSN, Susan Cutler DMD, Jayson
Rieger PhD, MBA, David K. Glover ME, PhD, Pamela Rumney RN, CCRC, Thomas F.
Haws, Gary Goldenberg MD

Page s481

PDF


MICROWAVE ENERGY FOR TREATMENT OF SUPERFICIAL AND IN SITU SQUAMOUS CELL
CARCINOMA

Mark S. Nestor, MD, PhD, Angelica Marrero-Perez, MD, Aysham Chaudry, DO, Robert
Vanaria

Page s482

PDF


EVALUATING THE SAFETY AND EFFICACY OF AMINOLEVULINIC ACID 20% TOPICAL SOLUTION
ACTIVATED BY BLUE LIGHT IN THE TREATMENT OF FACIAL CUTANEOUS SQUAMOUS CELL
CARCINOMA IN SITU

Aysham Chaudry, DO, Angelica Marrero-Perez, MD, Robert J. Vanaria, Vishnu
Bhupalam, Mark S. Nestor, MD, PhD

Page s483

PDF


EXPERT CONSENSUS-BASED RECOMMENDATIONS ON THE USE OF PHOTODYNAMIC THERAPY IN
ACTINIC KERATOSIS PATIENTS

Dr. Vishal A. Patel, Dr. Sarah T. Arron, Dr. Brian Berman, Dr. M. Shane Chapman,
Dr. Anokhi Jambusaria-Pahlajani, Dr. George Martin, Dr. Anthony M. Rossi, Dr.
Todd Schlesinger, Dr. Nathalie C. Zeitouni, Dr. Neal Bhatia

Page s484

PDF


SAFETY AND EFFICACY OF PHOTODYNAMIC THERAPY WITH ALA 10% TOPICAL GEL ACTIVATED
BY RED LIGHT VERSUS ALA 20% TOPICAL SOLUTION ACTIVATED BY BLUE LIGHT FOR THE
TREATMENT OF ACTINIC KERATOSIS ON THE UPPER EXTREMITIES: A BLINDED RANDOMIZED
STUDY

Dr. Payvand Kamrani, Dr. Maya Firsowicz, Dr. Misha Zarbafian, Dr. Kavita Darji,
Dr. Raheel Zubair, Dr. Lisa Ishii, Dr. Mitchel Goldman, Dr. Monica Boen

Page s485

PDF


PILOT STUDY UTILIZING SHORT CONTACT PROTOCOLS FOR TREATMENT OF ACTINIC KERATOSES
(AK) WITH ALA GEL-RED LIGHT PHOTODYNAMIC THERAPY (PDT)

Jessica Johnson, Jackson Hanna, Dr. Amy S. Nowacki, Sanjay Anand, Alan Shen, Dr.
Edward Maytin

Page s486

PDF


GENERALIZED PUSTULAR PSORIASIS


REAL-WORLD SAFETY OF SPESOLIMAB IN GENERALIZED PUSTULAR PSORIASIS: EVIDENCE FROM
AN EXPANDED ACCESS PROGRAM IN ARGENTINA

María Laura Galimberti, María Lapadula, Rosana Veira, Nichiren Pillai, Rafael
Sani Simões, Ana Rodriguez Castelli, Natalia Dominguez, Glenda Vilchez, Lucas
Sheridan, Amy Weatherill, Xuemei Ding

Page s487

PDF


SPESOLIMAB DECREASES GENERALIZED PUSTULAR PSORIASIS (GPP) BODY SURFACE AREA
(BSA) OVER TIME IN PATIENTS SWITCHING FROM CONVENTIONAL SYSTEMIC TREATMENTS:
RESULTS FROM THE EFFISAYIL® 2 TRIAL

Joseph Merola, Bruce Strober, Alice Gottlieb, Arash Mostaghimi, Jason Hawkes,
Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s488

PDF


SPESOLIMAB DECREASES GENERALIZED PUSTULAR PSORIASIS (GPP) BODY SURFACE AREA
(BSA) OVER TIME IN PATIENTS WITH VARIOUS LENGTHS OF DISEASE HISTORY: RESULTS
FROM THE EFFISAYIL® 2 TRIAL

Arash Mostaghimi, Bruce Strober, Joseph Merola, Alice Gottlieb, Boni Elewski,
Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s489

PDF


SPESOLIMAB INCREASES THE PERCENTAGE OF GENERALIZED PUSTULAR PSORIASIS (GPP)
PATIENTS WITH CLEAR SKIN OVER TIME AS MEASURED BY THE PHYSICIAN’S GLOBAL
ASSESSMENT FOR GPP (GPPGA): RESULTS FROM THE EFFISAYIL® 2 TRIAL

Alice Gottlieb, Bruce Strober, Joseph Merola, Arash Mostaghimi, Aaron Farberg,
Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s490

PDF


SPESOLIMAB DECREASES GENERALIZED PUSTULAR PSORIASIS (GPP) BODY SURFACE AREA
(BSA) OVER TIME: RESULTS FROM THE EFFISAYIL® 2 TRIAL

Bruce Strober, Joseph Merola, Alice Gottlieb, Arash Mostaghimi, Jennifer Hsiao,
Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s491

PDF


FOUR-WEEKLY DOSING INTERVALS WITH SUBCUTANEOUS SPESOLIMAB APPEAR TO BE REQUIRED
FOR OPTIMAL PREVENTION OF GENERALIZED PUSTULAR PSORIASIS FLARES: DATA FROM THE
EFFISAYIL® 2 AND EFFISAYIL® ON TRIALS

Diamant Thaci, Akimichi Morita, Bruce Strober, Tiago Torres, Andreas Pinter,
Angelo Marzano, James Krueger, Ming Tang, Patrick Hofmann, Christian Thoma, Mark
Lebwohl

Page s492

PDF


ACNE & ROSACEA


DERMAL AND SYSTEMIC PHARMACOKINETICS OF ORAL DFD-29 (MINOCYCLINE HYDROCHLORIDE
MODIFIED RELEASE CAPSULES, 40 MG) VS ORAL DOXYCYCLINE 40 MG IN HEALTHY SUBJECTS

Dr. Adelaide Hebert, Dr. Srinivas Sidgiddi

Page s493

PDF


EFFICACY AND SAFETY OF FIXED-DOSE CLINDAMYCIN PHOSPHATE 1.2%/ADAPALENE
0.15%/BENZOYL PEROXIDE 3.1% GEL IN PARTICIPANTS WITH MODERATE-TO-SEVERE ACNE:
THE PATIENT JOURNEY

Hilary Baldwin, Julie C. Harper, Joshua A Zeichner, Zoe D Draelos, Lawrence F
Eichenfield, Michael Gold, Linda Stein Gold, Leon H Kircik, Eric Guenin

Page s494

PDF


EFFICACY AND SAFETY OF FIXED-DOSE CLINDAMYCIN PHOSPHATE 1.2%/ADAPALENE
0.15%/BENZOYL PEROXIDE 3.1% GEL IN BLACK PARTICIPANTS WITH MODERATE-TO-SEVERE
ACNE

Valerie D Callender, Andrew F Alexis, Neal Bhatia, Julie C Harper, Eric Guenin,
Hilary Baldwin

Page s495

PDF


ANTIBACTERIAL ACTIVITY OF CLINDAMYCIN/BPO IN COMBINATION WITH ADAPALENE

Ahmed Gamal, Mohamed Eltoukhi, Ali Elabbasi , James Q Del Rosso, Mahmoud
Ghannoum

Page s496

PDF


EFFICACY AND SAFETY OF CLINDAMYCIN PHOSPHATE 1.2%/ADAPALENE 0.15%/BENZOYL
PEROXIDE 3.1% GEL: POST HOC ANALYSIS BY BASELINE DISEASE SEVERITY

Michael Gold, Edward (Ted) Lain, Julie C Harper, Hilary Baldwin, Linda Stein
Gold, Eric Guenin

Page s497

PDF


MISCELLANEOUS


ENVIRONMENTAL IMPACT AND SUSTAINABILITY ASSOCIATED WITH THE PRACTICE OF
DERMATOLOGY

Robert J. Vanaria, Vishnu Bhupalam, Angelica Marrero-Perez, MD, Aysham Chaudry,
DO, Nardin Awad, DO, Mark S. Nestor, MD, PhD

Page s498

PDF


PHARMACODYNAMIC EFFECTS AND EXPLORATORY EFFICACY OF AFIMETORAN, A TLR7/8
INHIBITOR, IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS

Jasmine Saini, Stanislav Ignatenko, Kristina Chadwick, Lin Zhu, Huynh Yen Thanh
Bach, Hazem Karabeber, Michelle Dawes, Melanie Harrison, Leon Carayannopoulos,
Gopal Krishna, Fareeda Hosein, Frédéric Baribaud

Page s499

PDF


EFFICACY AND SAFETY OF RUXOLITINIB CREAM FOR THE TREATMENT OF MODERATE TO SEVERE
CHRONIC HAND ECZEMA: TOP-LINE RESULTS FROM A 16-WEEK, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND STUDY

Matthew Zirwas, Philippa Halden, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Linda Stein
Gold

Page s500

PDF


WORLDWIDE CLINICAL AND REAL-WORLD EXPOSURE TO BARICITINIB

Ruth Ann Vleugels, Brittany Craiglow, Arash Mostaghimi, Elise Olsen, Angelina
Sontag, Karen Denning, Najwa Somani, Maria Hordinsky

Page s501

PDF


TARGETED 308-NM EXCIMER LASER A SAFE AND EFFECTIVE SOLUTION FOR INFLAMMATORY
SKIN DISORDERS

Mark Lebwohl, MD

Page s502

PDF


COSMETIC


NOVEL APPROACH TO FAT REDUCTION: A PHASE I STUDY EVALUATING SAFETY AND
TOLERABILITY OF STP705 IN ABDOMINOPLASTY

Angelica Marrero-Perez, MD, Robert J. Vanaria, Aysham Chaudry, DO, Mark S.
Nestor, MD, PhD

Page s503

PDF


MELANOMA


IN A PROSPECTIVE, MULTICENTER STUDY, THE 31-GEP IDENTIFIED PATIENTS AT INCREASED
RISK OF TUMOR RECURRENCE AND ADDED SIGNIFICANT PROGNOSTIC VALUE TO AJCC STAGING

Betty Hinderks Davis, Brian Martin, Sonia Morgan, Angela Wingfield

Page s504

PDF


NAIL UNIT DISORDERS


A NON-PRESCRIPTION NITRIC OXIDE RELEASING GEL DEMONSTRATES IN VITRO ANTI-FUNGAL
ACTIVITY AND SUPPORTS NAIL CLEARANCE IN PATIENTS WITH ONYCHOMYCOSIS

Gilly Regev, James Martins, Chris Miller

Page s505




PRURITUS & PRURIGO NODULARIS


DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES AS EARLY AS 1 MONTH AMONG ADULTS
WITH PRURIGO NODULARIS IN CLINICAL PRACTICE: INITIAL RESULTS FROM THE RELIEVE-PN
STUDY

Shawn G Kwatra, Ryan B Thomas, Donia Bahloul, Joseph Zahn, Samreen Arshad, Bruno
Martins, Min Yang, Jiaxuan Liu, Allister Ho, Sarina B Elmariah

Page s506

PDF


VITILIGO


TONE: A LARGE, PROSPECTIVE POST-APPROVAL STUDY INVESTIGATING THE REPIGMENTATION
OF STABLE VITILIGO LESIONS USING A POINT-OF-CARE AUTOLOGOUS CELL HARVESTING
DEVICE

Amit G. Pandya

Page s507

PDF


XEROSIS


CLINICAL EFFICACY OF A NEW MOISTURIZER CONTAINING CERAMIDES AND NATURAL
MOISTURIZING FACTORS ON SUBJECTS WITH EXTRA DRY, ITCHY SKIN

Zoe Diana Draelos, Lauren Guinaw, Stephen Lynch, Isabela Miulescu, Nada Baalbaki

Page s508

PDF
View All Issues



 



 



Make a Submission


SKIN is a bi-monthly, peer-reviewed, online medical journal dedicated to
providing an enhanced route to disseminate new dermatologic knowledge on all
aspects of cutaneous disease. The Journal is Open Access. ISSN: 2574-1624

IMPORTANT LINKS

 * About the Journal
 * Editorial Team
 * Submissions
 * Contact

CONTACT

 * Email: jofskin@gmail.com
 * Website: skin.dermsquared.com
 * Mailing Address: PO Box 569 Millwood NY 10546

OJS Hosting, Support, and Customization by: OpenJournalSystems.com
×

MODAL HEADER


Close